Markets:

Overview

News

Currencies

International

Treasuries

Bayer Aktienges ADR (OP:BAYRY)

12.58 -0.37 (-2.86%)

Streaming Delayed Price Updated: 11:26 AM EST, Jan 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Bayer Aktienges ADR

< Previous 1 2 3 4 5 6 7 Next >

The mRNA 2.0 Inflection: A Deep Dive into Moderna (MRNA) as it Faces a Critical 2026

January 16, 2026

As of January 16, 2026, Moderna, Inc. (NASDAQ: MRNA) stands at a critical crossroads. Once the poster child for the biotechnology industry’s rapid response to a global pandemic, the Cambridge-based...

Via Finterra

Beyond the Bailout: US Farm Groups Demand Structural Reform as USDA Unveils $12 Billion 'Bridge' Program

January 02, 2026

As the 2026 calendar year begins, the United States agricultural sector finds itself at a critical policy crossroads. On one hand, the U.S. Department of Agriculture (USDA) has just finalized the...

Via MarketMinute

Topics Economy Energy

Bayer Stock Fuels Hyper Bullish Retail Mood After Confirming New Stroke Study Met Key Goals Following 2023 Halt ↗

November 23, 2025

Via Stocktwits

FDA Signs Off On Bayer's New Lung Cancer Drug — Early Results Look Promising ↗

November 20, 2025

FDA grants accelerated approval to Bayer's Hyrnuo and full approval to Amgen's Imdelltra, expanding treatment options for advanced lung cancer.

Via Benzinga

Siemens Warns Currency Headwinds Will Hit 2026 Results; CEO Defends Mid-Term Target ↗

November 14, 2025

Via Benzinga

Daré Bioscience (DARE) Q3 2025 Earnings Transcript ↗

November 13, 2025

Daré Bioscience (DARE) Q3 2025 Earnings Transcript

Via The Motley Fool

Agricultural Conglomerate Bayer Confident In Long-Term Outlook Despite Litigation Risks ↗

November 12, 2025

Bayer's Q3 earnings rose on strong Crop Science and Pharma sales, with CEO Bill Anderson confident in meeting the company's upgraded 2025 guidance.

Via Benzinga

Top 3 Health Care Stocks You'll Regret Missing In October ↗

October 21, 2025

Via Benzinga

Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results ↗

October 20, 2025

Exelixis stock dips after Phase 3 data show modest survival gains from zanzalintinib and Tecentriq combo in colorectal cancer patients.

Via Benzinga

Agri-Science Giant Corteva Eyes Breakup To Shield Seed Unit From Future Risks: Report ↗

September 15, 2025

Corteva is exploring a breakup that would separate its seed and pesticide businesses. The move could reshape agriculture amid falling crop prices and rising costs.

Via Benzinga

Retail Turns Bearish On Bayer After $1.3B Kumquat Cancer Drug Deal ↗

August 12, 2025

Bayer and Kumquat Biosciences have signed an exclusive global license and collaboration to develop a KRAS G12D inhibitor, with potential milestone payments of up to $1.3 billion

Via Stocktwits

U.S. Current-Account Deficit Widens to $450 Billion Amid Trade Imbalances and Energy Imports

July 25, 2025

The United States current-account deficit expanded sharply to $450 billion in the first half of 2025, marking a renewed widening of the country's financial shortfall with the rest of the world. This...

Via MarketMinute

Topics Artificial Intelligence Economy Supply Chain

History of Recursion Pharmaceuticals, Inc.: AI‑Driven Drug Discovery Beginnings (NASDAQ:RXRX)

July 21, 2025

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) emerged in the 2010s as one of the pioneers in leveraging artificial intelligence (AI) and advanced data analytics to transform drug discovery and...

Via MarketMinute

Topics Artificial Intelligence

Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars ↗

June 23, 2025

Exelixis' STELLAR-303 trial shows zanzalintinib plus Tecentriq improved survival in colorectal cancer, with no new safety concerns reported.

Via Benzinga

Exelixis Catapults 14% On Positive Results For Next-Gen Colon Cancer Drug ↗

June 23, 2025

Shares surged Monday after the company said its next-generation cancer drug showed promise in a colon cancer study.

Via Investor's Business Daily

Bayer Profit Drops 35%, Launches Overhaul To Counter Generic Pressure ↗

May 13, 2025

Bayer Q1 profit declined to $1.45 billion, but earnings and sales topped estimates as pharma growth offset crop science headwinds and currency impacts.

Via Benzinga

FDA Grants Complete Approval To Bayer's Drug For Certain Type Cancer With Mutation ↗

April 10, 2025

Bayer's Vitrakvi receives full FDA approval based on solid tumor data showing sustained efficacy in NTRK fusion-positive patients.

Via Benzinga

Bayer Enters License Agreement With China’s Puhe BioPharma For Cancer Drug Candidate: Retail Stays Bullish ↗

March 26, 2025

Bayer’s Pharmaceuticals Division’s Head of Business Development and Licensing Juergen Eckhardt said the drug’s “highly selective targeting” of cancer cells while sparing healthy ones is “very...

Via Stocktwits

Bayer CEO: 2025 Will Be 'Most Difficult' Year In Turnaround Plan, Expects Improved Performance From 2026 Onwards ↗

March 05, 2025

Bayer reported Q4 adjusted EPS of $0.28, missing estimates, but sales beat forecasts. The company sees 2025 as a tough year, with growth expected from 2026.

Via Benzinga

Topics Earnings

Regeneron's Best-Selling Eye Drug Eylea's Higher Dose Formulation Meets Primary Goal In Another Form Of Retinal Disease Study ↗

December 17, 2024

Regeneron's EYLEA HD met key goals in the Phase 3 QUASAR trial for macular edema after retinal vein occlusion, with FDA submission expected in Q1 2025.

Via Benzinga

FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market ↗

November 25, 2024

FDA approves BridgeBio's Attruby for ATTR-CM. Phase 3 results highlight its effectiveness in reducing cardiovascular risks and improving life quality.

Via Benzinga

BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market ↗

November 19, 2024

BridgeBio's acoramidis shows significant reductions in mortality and hospitalizations in ATTR-CM patients, with no new safety concerns in long-term studies.

Via Benzinga

ORIC: Working with Two Pharma Giants, Analysts See +100% Upside

November 16, 2024

ORIC Pharmaceuticals is a stock analyst price targets currently signal double-bagger potential in. See what the excitement around this firm is all about.

Via MarketBeat

Bayer Seeks European Approval For Its Menopause Drug ↗

October 15, 2024

Bayer has submitted an MAA to the EMA for elinzanetant, targeting moderate to severe vasomotor symptoms linked to menopause. Phase 3 trials showed significant reductions in VMS and improved quality of...

Via Benzinga

Bayer Seeks European Approval For Third Indication For Cancer Drug Darolutamide ↗

October 14, 2024

Bayer is seeking EMA approval for darolutamide in metastatic hormone-sensitive prostate cancer, building on promising Phase III ARANOTE trial results. The treatment significantly lowers progression...

Via Benzinga

Week In Review: Zenas Raises $259 Million In IPO ↗

September 28, 2024

It was a quiet week for biotech news in the Chinese market. Here is a brief overview of the notable events that occurred during this time. Zenas BioPharma staged a rare US biopharma IPO worth $259...

Via Talk Markets

Topics Initial Public Offering

Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea ↗

September 23, 2024

Eylea is one of Regeneron's biggest moneymakers, and Amgen is looking to knock it off.

Via Investor's Business Daily

Bayer Targets Expanded Use Approval For Prostate Cancer Drug, Reveals Encouraging Data From Pivotal Study ↗

September 16, 2024

Bayer's Phase 3 ARANOTE trial showed darolutamide plus androgen deprivation therapy (ADT) reduced the risk of radiological progression or death in metastatic hormone-sensitive prostate cancer patients...

Via Benzinga

Roivant Sciences Unveils New 'Vant' Subsidiary For In-Licensed Pulmonary Hypertension Drug From Bayer ↗

September 10, 2024

Roivant Sciences has licensed worldwide rights to develop and commercialize Bayer's mosliciguat for an upfront payment of $14 million and up to $280 million in future milestone payments.

Via Benzinga

Why Is BridgeBio Pharma Stock Trading Higher On Friday? ↗

August 30, 2024

BridgeBio Pharma presented additional data from its Phase 3 ATTRibute-CM study of acoramidis in ATTR-CM at the European Society of Cardiology 2024, showing increased serum TTR levels in participants...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.